-
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
Not Recruiting
More
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study
conducted in patients with advanced CD20-associated hematological cancers for which the
investigator determines there to be no other higher priority therapies available.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Not Recruiting
More
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide,
carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large
B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called
vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers
vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability
of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and
etoposide, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving
chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large
B-cell lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Not Recruiting
More
This study will characterize the safety and clinical benefit of valemetostat tosylate in
participants with relapsed/refractory peripheral T-cell lymphoma, including
relapsed/refractory adult T-cell leukemia/lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Recruiting
More
This phase II/III trial compares the side effects and activity of oral azacitidine in
combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide,
doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating
patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP
includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the
lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes
prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy
drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as
oral azacitidine, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without
disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Stanford Investigators
View full details
-
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
Not Recruiting
More
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475)
monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. The primary
hypothesis of the study is that the complete response (CR) rate at the end of study
intervention according to Lugano 2014 response criteria is higher than conventional
chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Recruiting
More
The purpose of this study is to test the safety and efficacy of magrolimab in combination
with pembrolizumab in patients with Hodgkin lymphoma.
Lead Sponsor
Stanford Investigators
View full details
-
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Recruiting
More
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell
Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Stanford Investigators
View full details
-
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Not Recruiting
More
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase
1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics
(PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid
tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with
chemotherapy for evaluation in these patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Not Recruiting
More
The purpose of this research study is to evaluate a new drug pembrolizumab in combination
with chemotherapy, for the treatment of newly diagnosed Hodgkin lymphoma. The chemotherapy
regimen is called AVD and includes three drugs: adriamycin, vinblastin, dacarbazine.
Pembrolizumab is currently FDA approved for the treatment of some patients with melanoma,
lung cancer and head and neck cancer, but has not yet been approved for the treatment of
Hodgkins Lymphoma. The AVD regimen of chemotherapy is currently FDA approved for the
treatment of newly diagnosed Hodgkin lymphoma, but has not yet been investigated in
combination with pembrolizumab for this disease. For patients who have a new diagnosis of
Hodgkins Lymphoma, multi-agent chemotherapy is recommended. Also, for patients who do not
have a complete response to chemotherapy (meaning there is still evidence of disease on PET
scans performed at the end of treatment), radiation is sometimes recommended. Furthermore,
the rare patient who relapses after chemotherapy requires treatment with high dose
chemotherapy and a transplant.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ranjana Advani, M.D., 650-725-6456.
Stanford Investigators
View full details
-
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Recruiting
More
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for
people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out
what side effects occur when brentuximab vedotin and CHP are used together. A side effect is
anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three
drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat
certain types of PTCL.
Stanford Investigators
View full details
-
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Not Recruiting
More
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab
Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together
with low-dose radiation therapy works in treating patients with stage I or stage IIA
Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Wiley, 6507256432.
Lead Sponsor
Stanford Investigators
View full details
-
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Not Recruiting
More
A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that
yields better tracking of cancer treatment progress. PET/CT stands for positron emission
tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT
uses a new tracer, fluorothymidine, which is taken up by cells that are actively
proliferating or dividing such as cancer cells. We hope to learn whether this tracer is
superior to the conventional tracer for monitoring treatment of diffuse large B-cell lymphoma
(DLBCL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Phuong Pham, 650-725-9810.
Stanford Investigators
View full details
-
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving rituximab together with combination chemotherapy may kill more
cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination
chemotherapy works in treating patients with stage II, stage III, or stage IV diffuse large
B-cell non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate,
vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride,
vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses
high-energy x rays to kill cancer cells. Giving combination chemotherapy together with
radiation therapy may kill more cancer cells. Comparing results of imaging procedures, such
as PET scans and CT scans, done before, during, and after chemotherapy may help doctors
predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase II clinical trial studies how well chemotherapy based on PET/CT scan
works in treating patients with stage I or stage II Hodgkin lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 6507216977.
Stanford Investigators
View full details
-
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Not Recruiting
More
First study, at multiple clinical centers, exploring the effects of different combinations of
compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma
(DLBCL) and Follicular Lymphoma
Stanford is currently not accepting patients for this trial.
For more information, please contact Tessa Hapanowicz, 650-721-4096.
Stanford Investigators
View full details
-
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from
dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either
kill them or deliver radioactive tumor-killing substances to them without harming normal
cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is
more effective in treating non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given
together with combination chemotherapy to see how well they work in treating patients with
newly-diagnosed non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Not Recruiting
More
This phase I/II trial studies the side effects and best dose of lenalidomide when given
together with combination chemotherapy and to see how well they work in treating patients
with newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in
chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and
etoposide, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may
stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new
blood vessels necessary for cancer growth. Giving combination chemotherapy with lenalidomide
may be a better treatment for peripheral T-cell non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ranjana H. Advani, 650-725-6456.
Stanford Investigators
View full details
-
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Not Recruiting
More
This study will determine the maximum dose of KW-0761 administered intravenously that can be
given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or
cutaneous T-cell lymphoma(CTCL)and will see if it is effective in treating the disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Turner, 6507251202.
Stanford Investigators
View full details
-
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
Not Recruiting
More
The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell
lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or
by presence of biomarkers associated with the anti-tumor effects of Rituximab.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cynthia Glover, .
Stanford Investigators
View full details
-
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Not Recruiting
More
This phase II trial studies how well combination chemotherapy and pralatrexate works in
treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 6507362563.
Stanford Investigators
View full details
-
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
Not Recruiting
More
This phase II trial is studying how well giving rituximab together with combination
chemotherapy and 90-Yttrium ibritumomab tiuxetan works in treating patients with stage I or
stage II lymphoma. Drugs used in chemotherapy, such as prednisone, cyclophosphamide,
doxorubicin, and vincristine, work in different ways to stop cancer cells from dividing so
they stop growing or die. Monoclonal antibodies such as rituximab and yttrium 90-Yttrium
ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive
cancer-killing substances to them without harming normal cells. Combining a monoclonal
antibody with combination chemotherapy and a radiolabeled monoclonal antibody may kill more
cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office, 6504987061.
Stanford Investigators
View full details
-
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
Others interfere with the ability of cancer cells to grow and spread. Drugs used in
chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer
cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell
lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab
together with bendamustine and bortezomib is more effective than rituximab and bendamustine,
followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.
PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and
lenalidomide in treating previously untreated older patients with mantle cell lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Not Recruiting
More
The primary objectives of this study are:
- To investigate the safety and tolerability, and to define the recommended Phase 2 dose
and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in
combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx).
- To evaluate the efficacy of magrolimab in combination with rituximab in participants
with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the
efficacy of magrolimab in combination with R-GemOx in aspartate aminotransferase (ASCT)
ineligible DLBCL participants.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Not Recruiting
More
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in
humans.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 6507362563.
Stanford Investigators
View full details
-
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies,
such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells
from growing. It is not yet known whether giving bendamustine hydrochloride and rituximab
together alone is more effective than giving bendamustine hydrochloride and rituximab
together with bortezomib or lenalidomide in treating follicular lymphoma.
PURPOSE: This randomized phase II trial is studying giving bendamustine hydrochloride and
rituximab together with or without bortezomib followed by rituximab with or without
lenalidomide to see how well they work in treating patients with high-risk stage II, stage
III, or stage IV follicular lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Not Recruiting
More
This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older
patients with untreated Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Biological therapies, such as brentuximab vedotin,
use substances made from living organisms that may stimulate or suppress the immune system in
different ways and stop cancer cells from growing. Nivolumab and brentuximab vedotin may work
better in treating older patients with untreated Hodgkin lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ranjana H. Advani, .
Stanford Investigators
View full details
-
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
Not Recruiting
More
The purpose of this study is to evaluate the safety, tolerability and clinical activity of
RO6870810 in combination with venetoclax and when co-administered with rituximab in
participants with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and/or
high-grade B-cell lymphoma with myelocytomatosis oncogene (MYC) and/or B-cell lymphoma 2
(BCL2) and/or B-cell lymphoma 6 (BCL6) gene rearrangements (HGBL-DH/TH).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Not Recruiting
More
The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the
clinical outcome compared with standard of care second-line therapy in patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Not Recruiting
More
The purpose of this study is to assess the safety profile and antitumor activity of
brentuximab vedotin administered in combination with nivolumab in patients with relapsed or
refractory Hodgkin lymphoma (HL)
Stanford is currently not accepting patients for this trial.
For more information, please contact Jean Sabile, 650-723-0530 .
Stanford Investigators
View full details
-
Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.
Not Recruiting
More
Phase II study designed to investigate antitumor activity in terms of objective response rate
(ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will
be administered orally until disease progression.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 650-736-2563.
Stanford Investigators
View full details
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Not Recruiting
More
This randomized phase II trial studies how well rituximab and combination chemotherapy with
or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse
large B cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the
ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Lenalidomide may stimulate the immune
system in different ways and stop cancer cells from growing. It is not yet known whether
rituximab and combination chemotherapy are more effective when given with or without
lenalidomide in treating patients with diffuse large B cell lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Caitlin Plahn, 650-723-3046.
Stanford Investigators
View full details
-
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Not Recruiting
More
This study has two parts with distinct study objectives and study design. In part A,
odronextamab is studied as an intravenous (IV) administration with a dose escalation and a
dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study
are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a
subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 650-736-2563.
Stanford Investigators
View full details
-
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Not Recruiting
More
This research study is studying a targeted therapy as a possible treatment for relapsed or
refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention
ABT-199.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side
effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F
18-PET/CT imaging, may help doctors predict how patients will respond to treatment.
PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well
it works in assessing response to combination chemotherapy and allow doctors to plan better
additional further treatment in treating patients with stage III or stage IV Hodgkin
lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 6507216977.
Stanford Investigators
View full details
-
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Not Recruiting
More
The purpose of this study is to compare the outcomes across the 4 different treatment groups.
The investigators hope that this treatment will improve the ability to cure more patients
with HL and also limit the long-term side effects from the treatment. Although eliminating
radiation in cohort 4 will eliminate the risk for long-term side effects from radiation, it
is also possible that with BV+AVD chemotherapy alone there may be an increased risk of the
Hodgkin lymphoma coming back after initial treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ranjana Advani, MD, 650-498-6000.
Stanford Investigators
View full details
-
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
Not Recruiting
More
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
AGS67E both without and with myeloid growth factor (GF) in subjects with refractory or
relapsed lymphoid malignancies. Immunogenicity and anticancer activity of AGS67E will also be
assessed.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 650-736-2563.
Stanford Investigators
View full details
-
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Not Recruiting
More
The designed study follows up the retrospective previous one by the International T-cell
Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project).
It is designed as a prospective collection of information potentially useful to predict the
prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell
lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and
to better define clinical characteristics and outcome of the more uncommon subtypes
Stanford is currently not accepting patients for this trial.
For more information, please contact Kelsey Walters, 650-725-6432.
Stanford Investigators
View full details
-
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Not Recruiting
More
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in
combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is
an open-label, 2-stage study designed to determine the recommended dose level of bendamustine
in combination with brentuximab vedotin. The study will assess the safety profile of the
combination treatment and determine what proportion of patients achieve a complete remission.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Daadi, 650-723-6498.
Stanford Investigators
View full details
-
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Not Recruiting
More
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the
efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care
CHOP in patients with CD30-positive mature T-cell lymphomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 650-736-2563.
Stanford Investigators
View full details
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Not Recruiting
More
This phase II trial studies how well giving brentuximab vedotin together with combination
chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin
lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block
cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such
as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving brentuximab vedotin, doxorubicin hydrochloride, vinblastine, and dacarbazine
together may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Tessa Hapanowicz, 650-721-0273.
Stanford Investigators
View full details
-
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Not Recruiting
More
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen
of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small
lymphocytic leukemia (CLL/SLL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 650-736-2563.
Stanford Investigators
View full details
-
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Not Recruiting
More
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in
approximately 90% of the patients with Waldenström's macroglobulinemia. MYD88 is a key linker
protein in the signaling pathway of Toll Like Receptors (TLRs) 7, 8, and 9, and IMO-8400 is
an oligonucleotide specifically designed to inhibit TLRs 7,8, and 9. The scientific
hypothesis for use of IMO-8400 to treat patients with Waldenström's macroglobulinemia depends
on the inhibition of mutant MYD88 signaling in the TLR pathway, thereby interrupting the
proliferation of cell populations responsible for the propagation of the disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 650-736-2563.
Stanford Investigators
View full details
-
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
Not Recruiting
More
This study was to evaluate the safety and efficacy of a daily, oral dose of 10 mg RAD001 in
participants with Mantle Cell Lymphoma who were refractory or intolerant to Velcade® therapy
and who had received at least one prior antineoplastic agent other than Velcade®, either
separately or in combination with Velcade® (see inclusion criteria). Intolerance to Velcade®
therapy was determined by the study investigator based on clinical evaluations. Participants
were considered refractory to Velcade® if they have documented radiological progression on or
within 12 months of the last dose of Velcade® when given alone or, on or within 12 months of
the last dose of the last component of a combination therapy which included Velcade®.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 6507362563.
Stanford Investigators
View full details
-
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
Not Recruiting
More
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with
rituximab in participants with CD20-positive lymphoproliferative disorders. The extension
portion of the study will allow active participants to continue to receive ABT-263 for up to
13 years after the last participant transitions with quarterly study evaluations.
Stanford is currently not accepting patients for this trial.
For more information, please contact Euodia Jonathan, 6507256432.
Stanford Investigators
View full details
-
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Not Recruiting
More
The primary objective of this study was to evaluate the efficacy of ibrutinib in participants
with relapsed or refractory MCL.
The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg
daily) of PCI-32765 in this population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 6507362563.
Stanford Investigators
View full details
-
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Not Recruiting
More
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when
given together with brentuximab vedotin, and how well they work in treating patients with
Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not
responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such
as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a
monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab
attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them.
It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab
may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Caitlin Plahn, 650-723-3046.
Stanford Investigators
View full details
-
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Not Recruiting
More
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when
given with combination chemotherapy in treating patients with newly diagnosed stage III or IV
classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked
to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and
delivers vedotin to kill them. Chemotherapy drugs, such as doxorubicin, vinblastine, and
dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. The addition of
nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend
the time without disease symptoms coming back.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
